Education on Increased ICP Reduces Nursing ‘Headache’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

WASHINGTON-Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.

WASHINGTON—Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.

When turnover in the nursing staff left a neuro-oncology unit devoid of nurses knowledgeable in basic neurological assessment and experienced at identifying the signs and symptoms of increased intracranial pressure, an effective and convenient teaching method became imperative. A nurse-designed self-study module met the need, Ms. Baumgartner and her colleague Susan Hummel, RN, MN, CNS, reported at the Oncology Nursing Society (abstract 83) Congress.

Based on guidelines from the Brain Trauma Foundation, the module included a pretest, written instructional material, a post-test, and an evaluation form. Four experienced oncology nurses who were nonetheless new to neuro-oncology used the module in a pilot study. At pretest, the nurses correctly answered an average of only 60% of questions. After studying with the module, they averaged 90% correct. Their evaluations of the written material suggested revisions were needed to explain more specifically the pathophysiology of increased intracranial pressure. Once the module is approved for continuing education credit, it will be made available to other nurses at the facility, she said. 

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content